Navigation Links
Silence Therapeutics Announces Positive Response by USPTO that Affirms Validity of Four Foundational RNAi Patents
Date:12/12/2011

LONDON, December 12, 2011 /PRNewswire/ --

Silence Therapeutics plc (AIM: SLN) ("Silence" or the "Company"), a leading global RNA interference (RNAi) therapeutics company, announces that the United States Patent and Trademark Office (USPTO) has completed its reexamination of four key RNAi patents that form part of the foundational "Zamore Design Rule" patent families. Following a review requested by an anonymous third party during 2010, the USPTO has concluded that the reissued claims are patentable and has issued Notices of Intent to Issue Reexamination Certificates. The prior art cited in the reexaminations was unsuccessful in invalidating the patents.

The four patents (US 7,459,547, US 7,732,593, US 7,772,203 and US 7,750,144) form part of the foundational "Zamore Design Rule" patent families that disclose various efficacy-enhancing methods and structural elements for RNAi therapeutics. Silence has exclusively licensed three "Zamore Design Rule" patent families in their entirety for applications in the human healthcare field from the University of Massachusetts Medical School. The three patent families generally disclose methods of enhancing the silencing activity of RNAi agents through certain structural modifications. The claims associated with the reexaminations include coverage for methods of enhancing silencing of a pharmaceutical composition containing short interfering RNA (siRNA), micro RNA (miRNA), pre-miRNA or short hairpin RNA (shRNA) molecules.

Thomas Christély, Chief Executive Officer of Silence Therapeutics, said: "We are very pleased that the USPTO has reissued these four patents. This outcome sends a clear message regarding the strength of Silence's intellectual property. We believe that there is significant value in the Zamore technology as a fundament
'/>"/>

SOURCE Silence Therapeutics Plc
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Silence Therapeutics Announces Positive Outcome From Oral Hearing at the European Patent Office
2. Silence Therapeutics Provides Corporate and Development Update
3. Silence Therapeutics Signs Collaboration With Mirna Therapeutics to Evaluate Delivery of Novel microRNA Therapeutics
4. Silence Therapeutics Issued Japanese Patent Covering its Core RNA Interference (RNAi) Technology
5. Silence Therapeutics Lead RNA Interference Therapeutic Prevents Spread of Cancer to Lungs
6. Silence Therapeutics Receives Comprehensive Protection for RNAi Structural Modification Technology in Single European Patent
7. Silence Therapeutics Partner Quark Signs Exclusive Option Agreement With Novartis for Development and Commercialisation of QPI-1002
8. Silence Therapeutics Expands RNAi Structural Modification IP Portfolio With Issuance of New U.S. Patent
9. Silence Therapeutics Issued Novel RNAi Patent Covering High-Value Cancer Target in United States
10. Silence Therapeutics Appoints New Vice President of Research
11. Silence Therapeutics to Present at 12th Annual BIO CEO & Investor Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/20/2014)... 20, 2014 Clintrax Global, Inc., a ... Raleigh, NC , recently announced ... Vice President of Administration. As ... corporate processes, including their alignment with company objectives ... worked as an HR executive, specializing in needs ...
(Date:8/20/2014)... PLANTATION, Fla. , Aug. 20, 2014 /PRNewswire/ ... it will host a conference call to provide ... 26, 2014Time:4:30 p.m. Eastern daylight timeDial-in numbers:(888) 505-4369 ... number: 9126599 Live web cast: www.neurotropebioscience.com , under ... three hours after completion through September 2, 2014 ...
(Date:8/20/2014)... 20, 2014 The 6th Annual ... held on October 29-30 in San Francisco, CA. This ... and government researchers and clinicians focused on addressing and ... , In the twelve years since the sequencing of ... been introduced with pharmacogenetic information in the label and ...
(Date:8/20/2014)... August 20, 2014 WriteResult®, a leading ... that it has expanded its myPROpad™ ePRO tablet with ... one of the most widely used and well-respected ... health status. The EQ-5D is used during clinical trials ... measure that can be used to demonstrate Health-Related Quality ...
Breaking Biology Technology:Clintrax Global, Inc. Announces Addition to Executive Team 2Neurotrope To Host Conference Call 26th Annual Personalized and Precision Medicine Conference Bringing Together Thought Leaders to Discuss Clinical Implementation, Dx Reimbursement, Big Data, and Sequencing 2EQ-5D™ Assessment Now Available for iPad 2
... July 23 /PRNewswire-FirstCall/ - Roche,(SWX: ROG) and ARIUS ... have signed a definitive agreement for Roche to ... of approximately C$191 million. ARIUS is,the developer of ... and selects antibodies based on their functional,ability to ...
... ALTO, Calif., July 22 CV Therapeutics,Inc. (Nasdaq: ... quarter,financial results for 2008 after the market closes on ... call at 5:00 p.m. EDT,2:00 p.m. PDT, on the ... log on to the Company,s website at, http://www.cvt.com ...
... N.J., July 22 The Board of,Directors of BD ... declared a,quarterly dividend of 28.5 cents per common share. ... holders of record on September 9, 2008.,The indicated annual ... BD is a leading global medical technology company ...
Cached Biology Technology:Roche starts acquisition process of ARIUS to gain access to new screening platform for antibody therapeutics 2Roche starts acquisition process of ARIUS to gain access to new screening platform for antibody therapeutics 3Roche starts acquisition process of ARIUS to gain access to new screening platform for antibody therapeutics 4CV Therapeutics to Announce 2008 Second Quarter Financial Results on Thursday, July 31, 2008 2
(Date:8/19/2014)... German . ... a large amount of electricity is to be produced with ... to be stored during productive periods so that these fluctuations ... from adequate for the purpose. Science and industry are therefore ... battery systems that used to be too expensive or unsophisticated ...
(Date:8/19/2014)... lemur. It,s not an African Bush Baby or even a ... downright "cool" primate from Southeast Asia. , "It,s really not ... Brown, curator-in-charge at the University of Kansas, Biodiversity Institute. "A ... body; a long tail with a furry tuft at the ... a bit like the disks on the digits of tree ...
(Date:8/19/2014)... New measurements from fish purchased at retail seafood ... to which mislabeling can expose consumers to unexpectedly ... Fishery stock "substitutions"which falsely present a fish of ... originare the most dangerous mislabeling offense, according to ... scientists. , "Accurate labeling of seafood is essential ...
Breaking Biology News(10 mins):Asian inventions dominate energy storage systems 2Asian inventions dominate energy storage systems 3Philippine tarsier gets boost from Kansas research, and genetic proof of a new variety 2Philippine tarsier gets boost from Kansas research, and genetic proof of a new variety 3Seafood substitutions can expose consumers to unexpectedly high mercury 2Seafood substitutions can expose consumers to unexpectedly high mercury 3
... Canadian researcher working in the U.K. says doctors, authors ... claiming that hyperactivity as we understand it today has ... that notion wrong, it misleads patients, their parents and ... finishing up his PhD at the Centre for Medical ...
... embarrassing, but a new study suggests that it might ... interviewed more than three thousand men - all pairs ... - about the first time they had sex. Many ... from erectile dysfunction and premature ejaculation at their first ...
... for proposals, projects focus on either the development of ... and genomics. The Swiss National Science Foundation (SNSF) approved ... 47 research groups from both Swiss Federal Institutes of ... from the Universities of Basel, Lausanne, Geneva and Zurich. ...
Cached Biology News:History of hyperactivity off-base, says researcher 2Swiss Initiative in Systems Biology launches new projects 2
Wnt-1 (G-19)...
... G4-1, Affinity-Purified Polyclonal IgY Antibodies ... phosphatase subunit gene g4-1 Protein ... query: 8923600 Genbank Definition: ... likely ortholog of mouse phosphatase subunit gene ...
HSV-1 gE Envelope Protein (9H3)...
... C-terminal reactive. Cross-reacts fully with GLP-1(1-36) ... with the unamidated forms GLP-1(7-37) and ... as hGLP-2, glucagon, hGIP and VIP.,SPECIES ... identical in all mammalian species studied ...
Biology Products: